Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Основные результаты программы АПРЕЛЬ
Основные результаты программы АПРЕЛЬ
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Mikhail N, Golub M, Tuck M. Obesity and hypertension. Prog Cardiovasc Dis 1999; 42 (1): 39–58.
2. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation 1979; 59: 8–13.
3. DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European Studies. Diabetologia 1999; 42: 654–74.
4. Collins VR, Dowse G, Zimmet P. Evidence against asscociation between parity and NIDDM from five population groups. Diabetes Care 1991; 14: 975–81.
5. Tominaga M, Egushi H, Manaka H et al. Imparied glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22: 920–4.
6. Rosak C et al The effect of the timing and and the administration of acarbose on postprandial hyperglycaemia. Diab Med 1995; 12: 979–84.
7. Chazova I, Mychka V. Treatment of patients with arterial hypertension and impaired glucose tolerance: results from "APREL" study. Fifteenth European meeting on Hypertension, Milan, Italy, June 17–21, 2005; S121.
8. Jean-Louis Chiasson. Acarbose for prevention of type 2 diabetes mellitus: the Stop-NIDDM randomized trial. Lancet 2002; 358: 2072–7.
9. Jean-Louis Chiasson. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA 2003; 290: 486–94.
10. Steiner G. Altering triglyceride concentration changes insulin-glucose relationships in hypertriglyceridemic patients. Double-blind study with gemfibrozil with implications for atherosclerosis. Diabetes Care 1991; 14: 1077–81.
11. Mamo J, Szeto L, Steiner G. Glycation of very low density lipoprotein from rat plasma impairs its catabolism. Diabetologia 1990; 33: 339–43.
12. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987; 28: 613–28.
2. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation 1979; 59: 8–13.
3. DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European Studies. Diabetologia 1999; 42: 654–74.
4. Collins VR, Dowse G, Zimmet P. Evidence against asscociation between parity and NIDDM from five population groups. Diabetes Care 1991; 14: 975–81.
5. Tominaga M, Egushi H, Manaka H et al. Imparied glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22: 920–4.
6. Rosak C et al The effect of the timing and and the administration of acarbose on postprandial hyperglycaemia. Diab Med 1995; 12: 979–84.
7. Chazova I, Mychka V. Treatment of patients with arterial hypertension and impaired glucose tolerance: results from "APREL" study. Fifteenth European meeting on Hypertension, Milan, Italy, June 17–21, 2005; S121.
8. Jean-Louis Chiasson. Acarbose for prevention of type 2 diabetes mellitus: the Stop-NIDDM randomized trial. Lancet 2002; 358: 2072–7.
9. Jean-Louis Chiasson. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA 2003; 290: 486–94.
10. Steiner G. Altering triglyceride concentration changes insulin-glucose relationships in hypertriglyceridemic patients. Double-blind study with gemfibrozil with implications for atherosclerosis. Diabetes Care 1991; 14: 1077–81.
11. Mamo J, Szeto L, Steiner G. Glycation of very low density lipoprotein from rat plasma impairs its catabolism. Diabetologia 1990; 33: 339–43.
12. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987; 28: 613–28.
Авторы
И.Е.Чазова, В.Б.Мычка, Ю.Н.Беленков от имени исследователей программы АПРЕЛЬ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.